There was an average 74-fold increase in adaptor related protein complex 5 subunit zeta 1 (AP5Z1) (log2 fold = 6.201, P = 0.005), 53 fold increase in VPS8 subunit of CORVET complex (VPS8) (log2 fold = 5.730, P = 0.043), 19 fold increase in integrator complex subunit 6 INTS6 (log2 fold = 4.234, P = 0.041), 18 fold increase in calumenin (CALU) (log2 fold = 4.135, P = 0.012), 16 fold increase in insulin-like growth factor binding protein 5 (IGFBP5) (log2 fold = 4.008, P = 0.015), tenfold increase in RNA polymerase mitochondrial (POLRMT) (log2 fold = 3.355, P = 0.020), sevenfold increase in KIT proto-oncogene receptor tyrosine kinase (KIT) (log2 fold = 2.891, P = 0.033), sevenfold increase in ciliary rootlet coiled-coil, rootletin (CROCC) (log2 fold = 2.742, P = 0.043), sixfold increase in polymeric immunoglobulin receptor (PIGR) (log2 fold = 2.684, P = 0.041) GP levels at the end of 4th week during 4-week intermittent fasting compared with the levels before 4-week intermittent fasting
However, development was discontinued in 2007 after the largest Phase IIb trial failed to demonstrate statistically significant weight loss compared to placebo
Graphical abstract Schematic diagram showing the mechanism of SNEDDS-loaded VST and SNEDDS-loaded VST/HCTZ as potential treatment strategies for type-2 diabetes mellitus
The prevalence of metabolic comorbidities such as hypertension, diabetes, and hyperlipidemia increased annually among HBV patients
